PL2753306T3 - Stałe postacie dozowania (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-metylo-1hpirazol-1-ilo)fenylo)-2,2,2-trifluoroetoksy)pirymidyn-4-ylo)fenylo)propionianu etylu - Google Patents

Stałe postacie dozowania (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-metylo-1hpirazol-1-ilo)fenylo)-2,2,2-trifluoroetoksy)pirymidyn-4-ylo)fenylo)propionianu etylu

Info

Publication number
PL2753306T3
PL2753306T3 PL12780617T PL12780617T PL2753306T3 PL 2753306 T3 PL2753306 T3 PL 2753306T3 PL 12780617 T PL12780617 T PL 12780617T PL 12780617 T PL12780617 T PL 12780617T PL 2753306 T3 PL2753306 T3 PL 2753306T3
Authority
PL
Poland
Prior art keywords
phenyl
amino
propanoate
trifluoroethoxy
pyrazol
Prior art date
Application number
PL12780617T
Other languages
English (en)
Inventor
Jinling Chen
Matthew S. DEAVER
Richard J. Holl
Kalyan NUGURU
Original Assignee
Lexicon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2753306(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals, Inc. filed Critical Lexicon Pharmaceuticals, Inc.
Publication of PL2753306T3 publication Critical patent/PL2753306T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL12780617T 2011-10-17 2012-10-16 Stałe postacie dozowania (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-metylo-1hpirazol-1-ilo)fenylo)-2,2,2-trifluoroetoksy)pirymidyn-4-ylo)fenylo)propionianu etylu PL2753306T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547894P 2011-10-17 2011-10-17
EP12780617.2A EP2753306B1 (en) 2011-10-17 2012-10-16 Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
PCT/US2012/060338 WO2013059146A1 (en) 2011-10-17 2012-10-16 Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate

Publications (1)

Publication Number Publication Date
PL2753306T3 true PL2753306T3 (pl) 2021-04-06

Family

ID=47116458

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12780617T PL2753306T3 (pl) 2011-10-17 2012-10-16 Stałe postacie dozowania (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-metylo-1hpirazol-1-ilo)fenylo)-2,2,2-trifluoroetoksy)pirymidyn-4-ylo)fenylo)propionianu etylu

Country Status (19)

Country Link
US (4) US20130172376A1 (pl)
EP (2) EP2753306B1 (pl)
JP (1) JP6203182B2 (pl)
KR (1) KR102047788B1 (pl)
CN (1) CN103987381B (pl)
AU (1) AU2012326383B2 (pl)
BR (1) BR112014009308B1 (pl)
CA (1) CA2851862C (pl)
DK (1) DK2753306T3 (pl)
ES (1) ES2835722T3 (pl)
HU (1) HUE051585T2 (pl)
IL (1) IL231958B (pl)
MX (1) MX360191B (pl)
PL (1) PL2753306T3 (pl)
PT (1) PT2753306T (pl)
RU (1) RU2661402C2 (pl)
SG (1) SG11201401583YA (pl)
UA (1) UA114412C2 (pl)
WO (1) WO2013059146A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
EP3124098B1 (en) 2014-03-28 2022-02-23 NGK Insulators, Ltd. Monolithic separation membrane structure and method for producing same
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108883377B (zh) 2016-03-31 2021-05-07 日本碍子株式会社 多孔质支撑体、多孔质支撑体的制造方法、分离膜结构体以及分离膜结构体的制造方法
TW201818964A (zh) 2016-09-30 2018-06-01 瑞士商諾伊曼特醫療公司 使用色胺酸羥化酶抑制劑之方法
EP3363798A1 (en) 2017-02-20 2018-08-22 Esteve Química, S.A. Amorphous form of telotristat etiprate
BR112022010101A2 (pt) * 2019-12-31 2022-09-06 Pfizer R&D Uk Ltd Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona
CN117567449A (zh) 2020-10-13 2024-02-20 勃林格殷格翰国际有限公司 再加工方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PE20000559A1 (es) * 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
WO2005021000A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Solid oral dosage forms of gatifloxacin
TW200716137A (en) * 2005-06-09 2007-05-01 Wyeth Corp Tanaproget compositions containing ethinyl estradiol
CN101528202A (zh) * 2006-07-05 2009-09-09 特瓦制药工业有限公司 美金刚的药物组合物
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
TWI439457B (zh) * 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc (s)-2-胺基-3-(4-(2-胺基-6-((r)-1-(4-氯-2-(3-甲基-1h-吡唑-1-基)苯基)-2,2,2-三氟乙氧)-嘧啶-4-基)苯基)丙酸乙酯之固體形式與其使用方法
US8614222B2 (en) * 2008-11-13 2013-12-24 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating low bone mass diseases
EP2216016A1 (en) * 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
DK3222277T3 (da) * 2009-03-31 2020-05-11 Ligand Pharm Inc Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati

Also Published As

Publication number Publication date
BR112014009308A2 (pt) 2017-04-11
WO2013059146A1 (en) 2013-04-25
BR112014009308B1 (pt) 2022-05-03
HUE051585T2 (hu) 2021-03-01
US20210008068A1 (en) 2021-01-14
EP3763374A1 (en) 2021-01-13
NZ623423A (en) 2016-04-29
UA114412C2 (uk) 2017-06-12
NZ717137A (en) 2017-10-27
AU2012326383B2 (en) 2017-07-27
EP2753306A1 (en) 2014-07-16
CN103987381B (zh) 2017-07-04
PT2753306T (pt) 2020-11-11
KR102047788B1 (ko) 2019-11-22
MX360191B (es) 2018-10-24
EP2753306B1 (en) 2020-09-23
RU2014119866A (ru) 2015-11-27
SG11201401583YA (en) 2014-09-26
CN103987381A (zh) 2014-08-13
US20150157632A1 (en) 2015-06-11
US20130172376A1 (en) 2013-07-04
JP6203182B2 (ja) 2017-09-27
KR20140081872A (ko) 2014-07-01
AU2012326383A1 (en) 2014-04-24
CA2851862C (en) 2020-04-14
DK2753306T3 (da) 2020-12-14
IL231958B (en) 2018-06-28
JP2014532073A (ja) 2014-12-04
IL231958A0 (en) 2014-05-28
ES2835722T3 (es) 2021-06-23
RU2661402C2 (ru) 2018-07-16
CA2851862A1 (en) 2013-04-25
US11406635B2 (en) 2022-08-09
US20190000843A1 (en) 2019-01-03
MX2014004603A (es) 2014-05-12

Similar Documents

Publication Publication Date Title
IL231958A0 (en) Solid dosage forms of (s)-ethyl-2-amino-3-(4-(2-amino-6(r)-1-(4-chloro-2-(3-methyl-h1-pyrazol-1-yl )-2,2,2-trifluoroethoxy)pyrimidine-4-yl(phenyl)propanoate
IL272622A (en) Use of proton tyrosine kinase inhibitors
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
IL242279A0 (en) Compounds of 3-chloro-3]-n-(pyrimidine-2-ylamino)phenyl]substituted propanamide and their salts
ZA201400012B (en) Inhibitors of bruton's tyrosine kinase
ZA201308397B (en) Inhibitors of bruton's tyrosine kinase
SI2432472T1 (sl) 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AP3902A (en) Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
ZA201400739B (en) Inhibitors of bruton's tyrosine kinase
EP2884982A4 (en) SUBSTITUTED PHENYL MILZ TYROSINE CHINASE INHIBITORS
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
HUE042165T2 (hu) Új fuzionált pirimidin-származékok a tirozin kináz aktivitás gátlására
PT2797581T (pt) Formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metanossulfonil-etil]-4-acetilaminoisoindolino-1,3-diona
ZA201303049B (en) Crystalline forms of (s)-2-amino-3-(4-(2- amino-6-((r)-1(4-chloro-2-(3-methyl-1h-pyrazol-1-yl) phenyl)- 2, 2, 2-trifluoroethoxy)pyrimidin-4- yl)phenyl)propanoic acid
ITMI20110647A1 (it) Procedimento migliorato per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
SI2608789T2 (sl) Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina
TH148782B (th) รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate)
ZA201302996B (en) Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
HK1188394A (en) Formulations of phenyl uracil compounds
HK1197361A (en) Inhibitors of bruton's tyrosine kinase